ArticleBlood advances2019

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.

Daniel J Landsburg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.